Base de dados : HANSEN
Pesquisa : HANSENIASE/QUIMIOTER [Descritor de assunto]
Referências encontradas : 1722 [refinar]
Mostrando: 1 .. 20   no formato [Detalhado]

página 1 de 87 ir para página                         

  1 / 1722 HANSEN  
              next record last record
seleciona
para imprimir
Id:27311
Autor:Nishioka, Sergio de A.
Título:Acute renal failure and multidrug therapy for leprosy.
Fonte:Int. J. Lepr;65(2):259-260, Jun. 1997. .
Descritores:Hanseníase/quimioter
Hanseníase/prev
Falência Renal Aguda/ind quim
Falência Renal Aguda/epidemiol
Falência Renal Aguda/etiol
Localização:BR191.1


  2 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27310
Autor:Cunha, Maria da Graça S; Schettini, Antonio P. M; Pedrosa, Valderiza L; Cruz, Rossilene C. S; Sadahiro, Megumi.
Título:Regarding Brasil, et al. 's adverse effects in leprosy's WHO/MDT and paramedic's role in Leprosy Control Program.
Fonte:Int. J. Lepr;65(2):257-259, Jun. 1997. tab.
Descritores:Hanseníase/quimioter
Hanseníase/epidemiol
Hanseníase/prev
Organização Mundial da Saúde
Brasil/epidemiol
Localização:BR191.1


  3 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27307
Autor:Li, Huan-Ying; Hu, Lu-Fang; Huang, Wan-Biao; Liu, Guo-Cai; Yuan, Lian-Chao; Jin, Zheng; Li, Xiong; Li, Jin-Lan; Yang, Zhong-Min.
Título:Risk of relapse in leprosy after fixed-duration multidrug therapy.
Fonte:Int. J. Lepr;65(2):238-245, Jun. 1997. tab, mapas.
Resumo:Between 1986 and 1995, 8307 leprosy patients have completed fixed-duration multidrug therapy (FD-MDT) and were followed annually for possible relapse. The mean relapse rate for multibacillary (MB) leprosy is 0.15/1000 person-years (py) and for paucibacillary (PB) 0.55/1000 py. There is no difference in the relapse rates between patients with or without chemotherapy before FD-MDT. In MB patients, the five relapses occurred between 4 and 7 years; in PB patients, five relapses occurred at 4-5 years after FD-MDT. Six additional PB relapses self-reported 1-4 years after the 5-year surveillance period and were not included in the relapse rates. Most PB patients relapsed into MB due to wrong classification and insufficient therapy. For the known 62 irregular MB patients the cumulative relapse rate is 6.5%. (AU)^ien.
Descritores:Hanseníase/quimioter
Hanseníase/epidemiol
Hanseníase/prev
Quimioterapia Combinada
Limites:Humanos
Localização:BR191.1


  4 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27306
Autor:Li, Huan-Ying; Hu, Lu-Fang; Wu, Pei-Wei; Luo, Jiu-Si; Liu, Xue-Ming.
Título:Fixed-duration multidrug therapy in multibacillary leprosy.
Fonte:Int. J. Lepr;65(2):230-237, Jun. 1997. tab, mapas.
Resumo:Six-hundred-fifty-seven active multibacillary (MB) leprosy patients were put on fixed-duration multidrug therapy (FD-MDT) between 1985 and 1992 (190 had had no and 235 had had previous treatment with dapsone) and were followed for 5 years after therapy. Two relapses occurred during year 5 of surveillance and both had received dapsone prior to chemotherapy, giving an overall relapse rate of 0.08/100 person-years (py). Excluding the two relapses, 99.4% of the MB patients converted to smear negativity at year 6 after a regular course of FD-MDT. The relapse rate for 35 MB patients with an initial bacterial index (BI) of > 4 with 5 years of surveillance was 0.24/100 py. Reactions occurred more frequently during the first 6 months of MDT, decreasing gradually thereafter, and reaching 0 in year 4 of surveillance. The deformity rate at intake was 22.7% and only 1.8% of MB patients developed new deformities or an increased grade in deformity during therapy. (AU)^ien.
Descritores:Hanseníase/quimioter
Hanseníase/epidemiol
Hanseníase/prev
Quimioterapia Combinada
Limites:Humanos
Masculino
Feminino
Localização:BR191.1


  5 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27305
Autor:Mane, Ibrahima; Cartel, Jean-Louis; Grosset, Jacques-Henri.
Título:Field trial on efficacy of supervised monthly dose of 600mg rifampin, 400mg ofloxacin and 100mg minocycline for the treatment of leprosy; first results.
Fonte:Int. J. Lepr;65(2):224-229, Jun. 1997. tab.
Resumo:In 1995, a field trial was implemented in Senegal in order to evaluate the efficacy of a regimen based on the monthly supervised intake of rifampin 600 mg, ofloxacin 400 mg and minocycline 100 mg to treat leprosy. During the first year of the trial, 220 patients with active leprosy (newly detected or relapsing after dapsone monotherapy) were recruited: 102 paucibacillary (PB) (60 males and 42 females) and 118 multibacillary (MB) (71 males and 47 females). All of them accepted the new treatment (none requested to be preferably put under standard WHO/MDT), no clinical sign which could be considered as a toxic effect of the drug was noted, and none of the patients refused to continue treatment because of any clinical trouble. The compliance was excellent: the 113 patients (PB and MB) detected during the first 6 months of the trial have taken six monthly doses in 6 months, as planned. The rate of clearance and the progressive decrease of cutaneous lesions was satisfactory. Although it is too soon to give comprehensive results, it should be noted that no treatment failure was observed in the 56 PB patients who have completed treatment and have been followed up for 6 months. The long-term efficacy of the new regimen is to be evaluated on the rate of relapse during the years following the cessation of treatment. If that relapse rate is acceptable (similar to that observed in patients after treatment with current standard WHO/ MDT), the new regimen could be a solution to treat, for instance, patients very irregular and/or living in remote or inaccessible areas since no selection of rifampin-resistant Mycobacterium leprae should be possible (a monthly dose of ofloxacin and minocycline being as effective as a dose of dapsone and clofazimine taken daily for 1 month). Nevertheless, until longer term results of this and other trials become available, there is no justification for any change in the treatment strategy, and all leprosy patients should be put under standard WHO/MDT. (AU)^ien.
Descritores:Hanseníase/quimioter
Rifampina/admin
Rifampina/ef adv
Rifampina/uso terap
Ofloxacino/admin
Ofloxacino/ef adv
Ofloxacino/uso terap
Minociclina/admin
Minociclina/ef adv
Minociclina/uso terap
Limites:Humanos
Masculino
Feminino
Localização:BR191.1


  6 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27304
Autor:Saunderson, Paul R; Haile-Mariam, Negussie.
Título:Monitoring steroid use in a field program; possible process indicators.
Fonte:Int. J. Lepr;65(2):217-223, Jun. 1997. tab.
Resumo:Two new indicators are proposed in order to make the task of monitoring certain prevention of disability (POD) activities more straightforward. The indicators are very similar to the case detection rates and the cohort analyses already used in both leprosy and tuberculosis (TB) control; this makes them very simple to put into practice. Despite their simplicity, it is argued that these indicators can give important information about the implementation of POD activities in a routine field program and could, therefore, help in improving the quality of those services to patients. The indicators are the steroid start rate (SSR) and the steroid completion rate (SCR). A number of possible confounding factors have been looked at and they are not negligible. However, the case detection rates for new cases of leprosy and treatment completion rates for multidrug therapy (MDT) are subject to similar biases, which are well recognized and which have not detracted from the usefulness of these indicators in evaluating leprosy control activities. The POD indicators, if used with an awareness of the possible biases involved, can help to improve the quality of certain POD activities. (AU)^ien.
Descritores:Hanseníase/compl
Hanseníase/quimioter
Hanseníase/prev
Quimioterapia Combinada
Limites:Humanos
Masculino
Feminino
Localização:BR191.1


  7 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27277
Autor:Dasananjali, Krongkarn; Schreuder, Pieter A. M; Pirayavaraporn, Charoon.
Título:A study on the effectiveness and safety of the WHO/MDT regimen in the Northeast of Thailand; a prospective study, 1984-1996.
Fonte:Int. J. Lepr;65(1):28-36, Mar., 1997. tab.
Resumo:The aim of this prospective study was to determine the effectiveness and safety of the multidrug therapy as recommended by the World Health Organization (WHO/MDT) in 1982. One-hundred-eighty-eight newly diagnosed leprosy patients [130 paucibacillary (PB) and 58 multibacillary (MB) patients] from three provinces in northeastern Thailand were recruited into a study from April 1984 to March 1985. The study lasted until May 1996. The results showed that 182 patients finished their course of WHO/MDT, representing a treatment completion rate of 95%; 167 (122 PB and 45 MB) were released from surveillance (RFS); 82 PB patients were still available for follow up by the end of 1994 and 31 MB patients by May 1996. Two PB patients were diagnosed with a relapse, showing a relapse rate of 0.2 per 100 person-years at risk. After an average of 8 years of follow up, no MB relapses have been diagnosed. The proportion of patients with a WHO grade 2 disability among PB and MB patients increased from 4% and 8% at the start of treatment to 7% and 13% at last examination, respectively. It is concluded that the fixed-duration, 6-month WHO/MDT regimen for PB leprosy and the 24-month regimen for MB leprosy are effective, acceptable and safe, and that clinical activity, histopathological activity and/or a positive skin smear at release from treatment (RFT) have no bearing on the efficacy of the WHO/MDT regimens. The relapse rates are low and in accordance with most published data available to date. The importance of skin-smear services for a reliable classification (WHO PB/MB classification for control programs) is stressed. (AU)^ien.
Descritores:Hanseníase/clas
Hanseníase/quimioter
Organização Mundial da Saúde/org
Limites:Humanos
Masculino
Feminino
Adulto
Localização:BR191.1


  8 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27276
Autor:Wilder-Smith, Annelies; Wilder-Smith, Einar.
Título:Effect of steroid therapy on parameters of peripheral autonomic dysfunction in leprosy patients with acute neuritis.
Fonte:Int. J. Lepr;65(1):20-27, Mar., 1997. tab, graf.
Resumo:Recent electrophysiological studies on peripheral autonomic dysfunction in leprosy patients show a high prevalence of autonomic dysfunction as measured by abnormal vasomotor reflexes (VMR) and absent sympathetic skin response (SSR). Nothing is known about the reversibility of these autonomic parameters with treatment. Since there is evidence that small fiber function may be the most reversible component in neuropathies, we measured the effect of steroid treatment on autonomic parameters together with motor and sensory functions in leprosy patients with acute neuritis. Control subjects were investigated for repeatability testing of autonomic function. Due to a relatively high variability on repeat VMR testing in the controls, we defined a change in VMR testing as a change of > 30%. With this definition, the VMR of 14.8% of the patients improved, 75% remained unchanged, and 10.2% worsened. Absent SSR became positive in 16.6% and remained unchanged in 83.4%. Improvement in sensory motor functions was seen in 21.2% and 1.3% of the patients, respectively. (AU)^ien.
Descritores:Hanseníase/quimioter
Neurite/quimioter
Neurite/microbiol
Limites:Humanos
Localização:BR191.1


  9 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27243
Autor:Ji, Baohong.
Título:Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks.
Fonte:Int. J. Lepr;66(3):391-391, Sept. 1998. .
Descritores:Hanseníase/quimioter
Hansenostáticos/admin
Hansenostáticos/uso terap
Limites:Humanos
Masculino
Feminino
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n3/v66n3cor03.pdf - en.
Localização:BR191.1


  10 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27237
Autor:Stefani, Mariane M. A; Martelli, Celina M. T; Morais-Neto, Otaliba L; Martelli, Pierpaolo; Costa, Mauricio B; Andrade, Ana Lucia S. S de.
Título:Assessment of anti-PGL-I as a prognostic marker of leprosy reaction.
Fonte:Int. J. Lepr;66(3):356-364, Sept. 1998. tab, graf.
Resumo:The anti-phenolic glycolipid-I (PGL-I) assay as currently applied for leprosy is conceived as an early marker of asymptomatic infection, early disease diagnosis and cure monitoring. Its use as a prognostic marker of reaction is still a matter of controversy. We conducted a case-control study to investigate whether IgM and IgG anti-PGL-I antibodies could discriminate patients at increased risk of developing reactions. Eligible cases were untreated leprosy patients at the onset of type 1 and type 2 reactions recruited from among 600 concurrent, newly detected, untreated leprosy patients attending an outpatient clinic in central Brazil. For the patients with reaction, approximately the same number of leprosy cases without reaction matched as to bacterial index (BI), age and gender were randomly selected. Individuals without clinical leprosy were evaluated as healthy controls. Sera from type 1 reaction (N = 43) and type 2 reaction (N = 26) patients were tested by an ELISA using PGL-I synthetic disaccharide-BSA antigen and 1:300 sera dilution (cut-off point > or = 0.2 OD). Antibody profiles were evaluated by exploratory data analysis and reverse cumulative distribution curves. The IgG anti-PGL-I response did not have a defined pattern, being detected only at low levels. Our results indicate that leprosy patients, independently of their reactional status, produce high levels of IgM anti-PGL-I, demonstrating a strong correlation between the magnitude of antibody response and the BI. Patients with a higher BI were at least 3.4 times more prone to produce an antibody response compared to healthy controls. (AU)^ien.
Descritores:Hanseníase/quimioter
Hanseníase/imunol
ELISA/instrum
Imunoglobulina G/sangue
Imunoglobulina M/sangue
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n3/v66n3a06.pdf - en.
Localização:BR191.1


  11 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27225
Autor:Anon.
Título:Immunology.
Fonte:Int. J. Lepr;66(4):94A-111A, Dec. 1998. .
Conferência:Apresentado em: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998.
Descritores:Hanseníase/quimioter
Hanseníase/imunol
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4abs08.pdf - en.
Localização:BR191.1


  12 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27219
Autor:Anon.
Título:Chemotherapy.
Fonte:Int. J. Lepr;66(4):2A-18A, Dec. 1998. .
Conferência:Apresentado em: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998.
Descritores:Hanseníase/quimioter
Hanseníase/imunol
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4abs02.pdf - en.
Localização:BR191.1


  13 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27213
Autor:Grosset, J. H; Franzblau, Scott.
Título:Report of workshop on chemotherapy.
Fonte:Int. J. Lepr;66(4):595-596, Dec. 1998. .
Conferência:Apresentado em: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998.
Descritores:Hanseníase/quimioter
Hanseníase/imunol
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4repcur03.pdf - en.
Localização:BR191.1


  14 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27200
Autor:Saunderson, Paul.
Título:Report of workshop on organization of leprosy services under low-endemic conditions.
Fonte:Int. J. Lepr;66(4):574-575, Dec. 1998. .
Conferência:Apresentado em: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998.
Descritores:Hanseníase/diag
Hanseníase/quimioter
Hanseníase/prev
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4repcur01.pdf - en.
Localização:BR191.1


  15 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27198
Autor:Jacobson, Robert R.
Título:Report of workshop on defining the disease and antibacterial therapy.
Fonte:Int. J. Lepr;66(4):572-573, Dec. 1998. .
Conferência:Apresentado em: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998.
Descritores:Hansenostáticos/uso terap
Hanseníase/quimioter
Hanseníase/prev
Mycobacterium leprae/ef drogas
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4repcur01.pdf - en.
Localização:BR191.1


  16 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27165
Autor:Solomon, Samuel; Kurian, Nisha; Ramadas, Palani; Rao, Pamidipai Samuel Simon Sudar.
Título:Incidence of nerve damage in leprosy patients treated with MDT.
Fonte:Int. J. Lepr;66(4):451-456, Dec. 1998. tab.
Resumo:The incidence rates of sensory and motor impairments during and after multidrug therapy (MDT) are reported for a prospective cohort of patients who had no nerve damage at registration (N = 1621). Sensory and motor loss increased with age and both were high among multibacillary patients as compared with paucibacillary patients. The lateral popliteal (common peroneal) and posterior tibial nerves seem to be most affected for sensory loss; whereas the posterior tibial and ulnar nerves are mainly responsible for motor loss. No significant difference by gender was found. Implications for prevention of disability (POD) activities are discussed and suitable recommendations made. (AU)^ien.
Descritores:Hanseníase/quimioter
Hanseníase/epidemiol
Hanseníase/fisiopatol
Mycobacterium leprae/patogen
Limites:Humanos
Masculino
Feminino
Adolescente
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4a02.pdf - en.
Localização:BR191.1


  17 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27152
Autor:Pfaltzgraff, Roy E.
Título:The management of reaction in leprosy.
Fonte:Int J Lep;57(1):103-109, Mar. 1989. .
Resumo:Reaction and the subsequent development of neuritis is the basis for the majority of the disabilities and deformities that occur in leprosy. All possible means to prevent, to treat, and to reverse every reaction should be employed in all-out effort to ultimately effect as ideal a functional status for the patient as can be attained^ien.
Descritores:Hanseníase/quimioter
Hanseníase/imunol
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n1/v57n1edt03.pdf - en.
Localização:Br191.1


  18 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27136
Autor:Waters, Michael FR.
Título:Interpretation of published papers on controlled clinical trials.
Fonte:Int J Lepr;57(2):556-557, June 1989. .
Descritores:Hanseníase/quimioter
Limites:Humanos
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2cor02.pdf - en.
Localização:Br191.1


  19 / 1722 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27132
Autor:Becx-Bleuminck, Marijke.
Título:Operational aspects of multidrug therapy.
Fonte:Int J Lepr;57(2):540-551, June 1989. ^btab.
Descritores:Hanseníase/quimioter
Rifampina/uso terap
Amidas/uso terap
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2soalec02.pdf - en.
Localização:Br191.1


  20 / 1722 HANSEN  
              first record previous record
seleciona
para imprimir
Texto Completo-en
Id:27122
Autor:Girdhar, Anita; Mishra, Brajendra; Lavania, Ravinder K; Bagga, Ashok K; Malaviya, Govind N; Girdhar, Bhawneshwar K.
Título:Leprosy in infants - report of two cases.
Fonte:Int J Lepr;57(2):472-475, June 1989. ^bilus.
Descritores:Hanseníase/diag
Hanseníase/quimioter
Hanseníase/patol
Rifampina/uso terap
Dapsona/uso terap
Limites:Humanos
Feminino
Lactente
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a04.pdf - en.
Localização:Br191.1



página 1 de 87 ir para página                         
   


Refinar a pesquisa
  Base de dados : HANSEN Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information